Track record, structured for direct comparison.
CRO site design surfaces specific, comparable delivery evidence — enrolment rates, site network, phase experience — rather than a generic capabilities page repeating the same claims every competitor makes.
A sponsor deciding who runs their trial wants specific, comparable delivery data — enrolment rates, site network, phase experience — not a capabilities page repeating claims every competitor makes.
Sponsors shortlist CROs by therapeutic depth and track record, not by service category, which most CRO sites are still structured around. A layout template built for a different subsector was never asked to account for that.
An architecture built around comparable delivery evidence, a component system for enrolment and site-network data, and a review of where current claims are not backed by anything a sponsor can actually verify.
A sponsor evaluating who will run their trial wants specific delivery evidence — enrolment rates, site network, phase experience — structured for direct comparison, not a generic capabilities page making the same claims every competitor makes.
A contract research organisation’s website has to convince a sponsor that you can deliver a study, and simultaneously persuade investigators and site staff that working with you will not be an administrative burden. Those readers want different things: the sponsor wants therapeutic experience, delivery evidence and quality systems, while the site wants to know how payments work, what the training demands are and who they will actually speak to. Trying to serve both through one set of pages usually results in an entirely sponsor-facing site, and site recruitment then becomes a problem that marketing is blamed for and never given the tools to fix.
Most contract research websites summarise experience as a list of therapeutic areas and a set of totals. That satisfies nobody, because the sponsor’s question is narrower: have you run this indication, at this phase, in these countries, with endpoints like ours. Holding study experience as structured records — indication, phase, regions, patient numbers, and whatever detail your agreements permit — lets the site answer that question directly and lets each therapeutic area develop into a page substantial enough to stand on its own. It also means new experience updates the site by adding a record rather than by rewriting prose.
What comes up when scoping a site for this category.
Typically a sponsor evaluation team comparing several delivery partners at once, arriving with search intent closer to “CRO therapeutic area capability” than to a general pharmaceutical query. That reader scans for study volume, site network reach, and regulatory track record within the first screen, not brand messaging, so those specifics need to surface immediately rather than being eased into further down the page.
It should present study volume, therapeutic area experience, and site network reach as structured, comparable data rather than narrative case studies alone. Sponsors shortlist quickly, so filterable capability tables and named trial examples let them assess fit within minutes. Testimonials can support that evidence but should not replace it, since procurement teams are trained to look past general endorsement toward verifiable specifics.
Yes — beyond the marketing site, that includes sponsor portals for document sharing, study-status dashboards, and content built around specific therapeutic areas rather than generic capability statements. See CRO for the full range of platforms and content we build for this sector, most of which extends directly from what starts on the public site.
Yes — a login-gated area for document sharing or study-status updates is a common addition alongside the public marketing site. It typically sits on a separate access path with its own permissions, so sponsor-specific material never surfaces in public search results, and each account only sees documentation relevant to its own active studies.
More than the anonymised summary most contract research organisations settle for. Indication, phase, region, approximate size, design features and delivery metrics can generally be presented without identifying a sponsor, particularly when aggregated across several studies. What that gives an evaluator is a pattern of relevant experience rather than a claim of it. The alternative — a page that says you have deep experience across therapeutic areas — is indistinguishable from every competitor and gives a sponsor nothing to compare.
A template that was never built for a sponsor comparing several delivery partners at once specifically. Tell us what you have and we will tell you what a structural fix would look like. Tell us your situation and we will tell you what a rebuild for a sponsor comparing several delivery partners at once would actually change.